JP2001515920A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001515920A5 JP2001515920A5 JP2000510776A JP2000510776A JP2001515920A5 JP 2001515920 A5 JP2001515920 A5 JP 2001515920A5 JP 2000510776 A JP2000510776 A JP 2000510776A JP 2000510776 A JP2000510776 A JP 2000510776A JP 2001515920 A5 JP2001515920 A5 JP 2001515920A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- sequence
- seq
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19739685.2 | 1997-09-10 | ||
| DE19739685A DE19739685A1 (de) | 1997-09-10 | 1997-09-10 | Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile |
| PCT/EP1998/005759 WO1999012971A2 (de) | 1997-09-10 | 1998-09-10 | Aminosäuresequenzen zur therapie und prophylaxe von erkrankungen durch clostridium difficile toxine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001515920A JP2001515920A (ja) | 2001-09-25 |
| JP2001515920A5 true JP2001515920A5 (https=) | 2006-01-05 |
| JP4318398B2 JP4318398B2 (ja) | 2009-08-19 |
Family
ID=7841840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000510776A Expired - Fee Related JP4318398B2 (ja) | 1997-09-10 | 1998-09-10 | クロストリジウム・ディフィシレ・トキシンａ |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6667035B1 (https=) |
| EP (1) | EP0994904B1 (https=) |
| JP (1) | JP4318398B2 (https=) |
| CN (1) | CN1273588A (https=) |
| AT (1) | ATE254139T1 (https=) |
| AU (1) | AU9742698A (https=) |
| BR (1) | BR9815367A (https=) |
| CA (1) | CA2303202C (https=) |
| DE (2) | DE19739685A1 (https=) |
| ES (1) | ES2210832T3 (https=) |
| WO (1) | WO1999012971A2 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19739685A1 (de) * | 1997-09-10 | 1999-03-11 | Eichel Streiber Christoph Von | Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile |
| WO2002062379A2 (en) * | 2001-02-09 | 2002-08-15 | The Provost, Fellows And Scholars Of The College Of The Holy And Unidivided Trinity Of Queen Elizabeth | Clostridium difficile vaccine |
| GB0130267D0 (en) * | 2001-12-19 | 2002-02-06 | Neutec Pharma Plc | Focussed antibody technology |
| GB0205206D0 (en) * | 2002-03-06 | 2002-04-17 | Oxoid Ltd | Synthetic peptides |
| GB0309126D0 (en) * | 2003-04-17 | 2003-05-28 | Neutec Pharma Plc | Clostridium difficile focussed antibodies |
| LT2857418T (lt) | 2004-02-06 | 2017-09-25 | University Of Massachusetts | Antikūnai prieš clostridium difficile toksinus ir jų panaudojimas |
| ATE385423T1 (de) * | 2004-06-16 | 2008-02-15 | Straumann Holding Ag | Abdeckmembran |
| GB0414886D0 (en) | 2004-07-02 | 2004-08-04 | Neutec Pharma Plc | Treatment of bacterial infections |
| US20090087478A1 (en) * | 2004-12-27 | 2009-04-02 | Progenics Pharmaceuticals (Nevada), Inc. | Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them |
| CA2618796C (en) | 2005-08-11 | 2018-01-02 | Arpi Matossian-Rogers | Peptides for treatment and diagnosis of autoimmune disease |
| AU2012241141B2 (en) * | 2005-08-11 | 2015-08-20 | Arpi Matossian-Rogers | TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease |
| CA2680741A1 (en) | 2007-03-22 | 2009-01-15 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| US20090280134A1 (en) * | 2008-05-09 | 2009-11-12 | Recopharma Ab | Compositions and methods for inhibiting toxin a from clostridium difficile |
| DE102008029688B4 (de) * | 2008-06-24 | 2016-06-23 | Biodics Gmbh | Verfahren zum Nachweis und zur Identifikation eines varianten C. difficile Stammes in einer Probe |
| WO2010014854A2 (en) | 2008-07-31 | 2010-02-04 | The Regents Of The University Of California | Antibodies that neutralize botulinum neurotoxins |
| US8889363B2 (en) | 2009-07-27 | 2014-11-18 | Biodics | Method for the detection and identification of a variant C. difficile strain in a sample |
| CA2768528C (en) * | 2009-07-27 | 2017-05-23 | Christoph Von Eichel-Streiber | Method for detecting and identifying a variant c. difficile strain in a sample |
| WO2011060076A1 (en) * | 2009-11-10 | 2011-05-19 | Amgen Inc. | Anti-c-mpl antibodies |
| US9243057B2 (en) | 2010-08-31 | 2016-01-26 | The Regents Of The University Of California | Antibodies for botulinum neurotoxins |
| WO2012118693A1 (en) * | 2011-02-28 | 2012-09-07 | Northshore University Healthsystem | Methods of diagnosing clostridium difficile infection |
| AR086199A1 (es) | 2011-04-22 | 2013-11-27 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos |
| US9505847B2 (en) * | 2011-08-22 | 2016-11-29 | Cnj Holdings Inc | Clostridium difficile antibodies |
| US10364298B2 (en) | 2011-11-18 | 2019-07-30 | National Research Council Of Canada | Clostridium difficile lipoteichoic acid and uses thereof |
| HK1200463A1 (en) * | 2012-03-02 | 2015-08-07 | 瑞泽恩制药公司 | Human antibodies to clostridium difficile toxins |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| CN109776676A (zh) * | 2012-11-28 | 2019-05-21 | Cnj控股公司 | 针对艰难梭菌的抗体 |
| EP4079760A3 (en) | 2013-03-15 | 2023-01-25 | Sanofi Pasteur Inc. | Antibodies against clostridium difficile toxins and methods of using the same |
| EP4168032A2 (en) | 2020-06-19 | 2023-04-26 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879218A (en) | 1982-09-13 | 1989-11-07 | Virginia Tech Intellectual Properties, Inc. | Antibody for C.difficile |
| DE3471661D1 (en) | 1984-03-02 | 1988-07-07 | Tracy Dale Wilkins | Toxins and antibodies of c. difficile |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4863852A (en) | 1985-07-03 | 1989-09-05 | Virginia Tech Intellectual Properties, Inc. | Method of detecting, isolating and purifying clostridium difficile toxin A and its receptors |
| US5071759A (en) * | 1986-05-30 | 1991-12-10 | The United States Of America As Represented By The Secretary Of The Army | Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B |
| US5580774A (en) * | 1989-07-31 | 1996-12-03 | Eli Lilly And Company | Chimeric antibodies directed against a human glycoprotein antigen |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5098826A (en) | 1990-03-09 | 1992-03-24 | Virginia Tech Intellectual Properties, Inc. | Detection, isolation and purification of Clostridium difficile toxin A with toxin receptors |
| US5231003A (en) * | 1990-05-11 | 1993-07-27 | Cambridge Bioscience Corporation | Monoclonal antibodies specific for toxin b of clostridium difficile |
| US5858725A (en) | 1990-10-10 | 1999-01-12 | Glaxo Wellcome Inc. | Preparation of chimaeric antibodies using the recombinant PCR strategy |
| GB9109645D0 (en) * | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
| GB9317423D0 (en) * | 1993-08-21 | 1993-10-06 | Imp Cancer Res Tech | Monoclonal antibodies |
| CA2203504A1 (en) * | 1994-10-24 | 1996-05-02 | James A. Williams | Vaccine and antitoxin for treatment and prevention of c. difficile disease |
| DE19739685A1 (de) * | 1997-09-10 | 1999-03-11 | Eichel Streiber Christoph Von | Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile |
-
1997
- 1997-09-10 DE DE19739685A patent/DE19739685A1/de not_active Ceased
-
1998
- 1998-09-10 AU AU97426/98A patent/AU9742698A/en not_active Abandoned
- 1998-09-10 CA CA2303202A patent/CA2303202C/en not_active Expired - Fee Related
- 1998-09-10 JP JP2000510776A patent/JP4318398B2/ja not_active Expired - Fee Related
- 1998-09-10 ES ES98951374T patent/ES2210832T3/es not_active Expired - Lifetime
- 1998-09-10 CN CN98808996A patent/CN1273588A/zh active Pending
- 1998-09-10 US US09/508,413 patent/US6667035B1/en not_active Expired - Fee Related
- 1998-09-10 EP EP98951374A patent/EP0994904B1/de not_active Expired - Lifetime
- 1998-09-10 DE DE59810172T patent/DE59810172D1/de not_active Expired - Lifetime
- 1998-09-10 AT AT98951374T patent/ATE254139T1/de active
- 1998-09-10 BR BR9815367-6A patent/BR9815367A/pt not_active Application Discontinuation
- 1998-09-10 WO PCT/EP1998/005759 patent/WO1999012971A2/de not_active Ceased
-
2003
- 2003-12-23 US US10/745,102 patent/US7151159B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001515920A5 (https=) | ||
| ATE494795T1 (de) | Verbessertes bioaktives molkeproteinhydrolysat | |
| WO2001079460A3 (en) | Polypeptides having haloperoxidase activity | |
| WO1999057280A3 (en) | Neisseria meningitidis antigens and compositions | |
| DE69906075D1 (de) | Salzbeständige modifizierte stärke | |
| DE69936774D1 (de) | Strukturproteine des virus, welches die pankreas-krankheit bei fischen verursacht, und ihre verwendungen | |
| MXPA03002926A (es) | Proceso para la sintesis de 2,2,6,6,-tetrametil-4--oxipiperidina. | |
| WO2002083727A3 (de) | Nukleinsäuresequenzen von hyperplasien und tumoren der schilddrüse | |
| DE50309337D1 (de) | Calcium enthaltende süssigkeit | |
| GB2364492B (en) | Audio processing, e.g. for discouraging vocalisation or the production of complex sounds | |
| NO20043665L (no) | Fremgangsmate for fremstilling av 6.alfa.,9.alfa-difluor-17.alfa.-(1-okso-propoksy-11.beta.-hydroxy-16.alfa.-metyl-3-okso-androst-1,4-dien-17.beta.-tiokarboksylsyre | |
| GB9929519D0 (en) | Audio processing,e.g.for discouraging vocalisation or the production of complex sounds | |
| WO2001070808A3 (en) | Angiogenesis - associated proteins, and nucleic acids encoding the same | |
| NO20011961D0 (no) | PRV-1-genet og anvendelsen av dette | |
| WO2003012106A3 (fr) | Acide nucleique regulateur permettant l'expression d'un polynucleotide d'interet specifiquement dans l'endothelium d'une graine de plante, et ses applications. | |
| WO2003057898A3 (en) | Methods and materials for modulating p2x2 | |
| DE60033562D1 (de) | Künstliche promotoren zür protein expression in pflanzen | |
| GB9823457D0 (en) | Audio processing, e.g. for discouraging vocalisation or the production of complex sounds | |
| WO2002034901A3 (en) | Protein kinase | |
| WO2002046380A3 (en) | Protein kinase |